The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", 10 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Regeneron Pharmaceuticals Inc is $816.79, about 17.5% above its July 29 closing price of $695.42
The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 16 three months ago
REGN•
